Trimedyne

HOME

ABOUT US

PRODUCTS

EDUCATION & TRAINING

INVESTOR RELATIONS

EVENTS

 

Company History

Management Team

Press Releases

Contact Us

Careers

 


Laser Spine Therapy
Provider List


 

 

FOR IMMEDIATE RELEASE

CONTACT: CRAIG SMITH

949.951.3800 EXT. 288
csmith@trimedyne.com
 

TRIMEDYNE'S CHAIRMAN INTERVIEWED BY WALL STREET REPORTER 

       September 1, 2004 – Irvine, CA: TRIMEDYNE, INC. (Symbol “TMED”) today announced its Chairman, Marvin P. Loeb, was interviewed by the Wall Street Reporter.  Mr. Loeb described the Company’s products, medical applications and financial results.  The audio interview will be posted on the http://www.wallstreetreporter.com web site through September 7, 2004.

       Trimedyne recently reported its seventh consecutive quarterly profit.  It manufactures Holmium Lasers and Optical Fibers for fragmenting stones in the kidney, ureter or bladder, and Laser Needles for use in new, outpatient procedures to treat herniated or ruptured discs in the spine.

       “In our disc procedures, the patient’s back pain usually disappears during or shortly after the approximate 20 to 40 minute procedure, and the patient typically walks out with only a band-aid on the puncture, no stitches, and is back to light activities in a few days.  Surgery to treat these conditions generally requires a two-to-seven day hospital stay, a lengthy, recuperation period and a long absence from work,” Loeb said.

       “An estimated 10 million people in the United States suffer from back pain, most often from a damaged or diseased spinal disc,” Loeb added.

       To hear the entire interview, visit www.wallstreetreporter.com, log in and click on Trimedyne.  For more information on Trimedyne, visit www.trimedyne.com.

 "Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

       Statements in this news release and the audio interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934.  Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports.  There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.     

*****

Back


Home | About Us | Products | Education & Training | Investor Relations | Events
  What's New | Careers | DoublePulse | Site Map | Contact Us

© Copyright 2004 Trimedyne, Inc.  All rights reserved.